Zydus receives final approval from USFDA for Bosentan tablets for oral suspension, 32 mg
Bosentan 32 mg tablets for oral suspension are indicated for the treatment of Pulmonary Arterial Hypertension
Bosentan 32 mg tablets for oral suspension are indicated for the treatment of Pulmonary Arterial Hypertension
mNEXSPIKE is the third Moderna vaccine authorized in the European Union, strengthening the Company's respiratory vaccine portfolio in Europe
Semaglutide is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus
Nucala is the first and only monthly biologic in the EU evaluated in a wide COPD population with an eosinophilic phenotype
The approved scheme will deliver around 1 million sq ft of state-of-the-art laboratory and research space across a 12-acre site
A PRV is a tradable voucher granted by the FDA to encourage the development of new treatments for rare pediatric diseases
NATCO’s Erdafitinib is indicated for the treatment of adult patients with locally advanced unresectable or metastatic urothelial carcinoma harbouring susceptible FGFR3 genetic alteration
Eltrombopag tablets will be produced at the group’s formulation manufacturing facility at SEZ, Ahmedabad
Subscribe To Our Newsletter & Stay Updated